Key Takeaways
- Shares of Stryker (SYK) plummeted 8.9%, reaching a 52-week low of $275.10 during Wednesday’s trading session
- Wells Fargo reduced its price objective from $418 down to $348, though maintained its Overweight stance
- The investment bank revised its 2026 revenue projection to $27,209M, falling short of the company’s forecasted range
- Wall Street maintains a “Moderate Buy” rating overall, with an average price objective of $386.28
- Company insiders offloaded more than 351,000 shares valued at approximately $118.2 million during the previous quarter
Stryker (SYK) experienced a sharp decline of 8.9% on Wednesday, closing at $276.16 after hitting an intraday 52-week low of $275.10. The medical device manufacturer’s shares now sit significantly beneath both its 50-day moving average of $327.52 and 200-day moving average of $328.30.
The steep decline followed Wells Fargo‘s decision to reduce its price objective on SYK from $418 to $348, while maintaining its Overweight designation. This adjustment came after Stryker participated in the 2026 Wells Fargo Healthcare Conference held in Boston, where CFO Preston Wells and VP of Investor Relations Nick Mead spoke on behalf of the organization.
The financial institution reduced its 2026 revenue forecast to $27,209 million from its previous estimate of $27,325 million. This projection suggests organic growth of 8.1%, falling below Stryker’s projected guidance corridor of 8.3% to 9.3%.
Additionally, Wells Fargo decreased its Q3 organic growth projection to 8.9% from 10.1%. The bank pointed to ongoing challenges in peripheral vascular products and hip and knee divisions worldwide throughout the remainder of the fiscal year.
The revised adjusted EPS forecast for 2026 now stands at $14.95, down from $15.02, positioning it at the lower boundary of Stryker’s guidance range of $14.95 to $15.10.
Wall Street Maintains Cautiously Optimistic Stance
Notwithstanding the downward pressure, the broader analyst community remains constructive on Stryker. The stock maintains a “Moderate Buy” consensus, supported by one Strong Buy recommendation, seventeen Buy ratings, and six Hold designations from market analysts.
The consensus price objective stands at $386.28, representing substantial upside from current trading levels. Piper Sandler maintained its Overweight designation while reducing its target to $390. JPMorgan decreased its objective to $350, also preserving its Overweight rating. Leerink Partners continues with an Outperform rating alongside a $407 target.
Stryker most recently disclosed Q2 2026 financial results on July 30th. The company posted adjusted EPS of $3.69, surpassing analyst expectations of $3.49 by $0.20. Total revenue reached $6.59 billion, marginally exceeding the consensus estimate of $6.58 billion.
Quarterly revenue increased 9.4% on a year-over-year basis. Earnings per share expanded 18% versus the comparable period in the prior year.
In response to these results, Wolfe Research elevated its price target to $375 from $350 while retaining an Outperform rating. Conversely, Citizens reduced its target to $400 from $440, referencing supply chain disruptions and a cyberattack incident that occurred earlier in the fiscal year.
Notable Insider Transaction Activity
Insider transactions have drawn market attention recently. During the most recent quarter, company insiders disposed of 351,267 shares totaling approximately $118.2 million in value.
Insider Debra King divested 826 shares on August 18th at a price of $336.30 per share. Dylan Crotty sold 441 shares on August 21st at $328.61 per share. Company insiders collectively maintain ownership of 4.60% of outstanding shares.
Regarding institutional movements, California State Teachers Retirement System significantly expanded its position during Q2. The pension fund currently maintains 163.4 million shares with an estimated value of approximately $51.4 billion.
Stryker announced a quarterly dividend distribution of $0.88 per share, scheduled for payment on October 30th to shareholders registered as of September 30th. The annualized dividend totals $3.52, translating to a yield of approximately 1.3%.
Management has established full-year 2026 EPS guidance in the range of $14.95 to $15.10. The analyst community’s consensus forecast stands at $15.03 for the current fiscal year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
